l CUX1 deficiency leads to transient clonal expansion followed by HSC depletion, anemia, and trilineage dysplasia.
Introduction
Monosomy 7 (27) and del(7q) are frequent, adverse-risk cytogenetic abnormalities in diseases of hematopoietic stem and progenitor cells (HSPCs). 27/del(7q) occurs across the spectrum of myeloid disorders, from bone marrow (BM) failure to overt leukemia, and typically carries an adverse prognosis. Fourteen percent of adult and 30% of pediatric myelodysplastic syndrome (MDS) patients have 27/del(7q).
1,2 Among inherited and acquired BM failure syndromes, 27/del(7q) develops in 40% to 80% of cases that evolve to MDS or acute myeloid leukemia (AML). 3 27/del(7q) occurs in 10% to 15% of de novo AML 4 and 49% of therapyrelated myeloid neoplasms. 5 In addition, 27/del(7q) is identified in 33% of juvenile myelomonocytic leukemia (JMML) and 14% of chronic myelomonocytic leukemia (CMML), which are myelodysplastic/ myeloproliferative neoplasms (MDS/MPN). 2, 6 Regardless of the disease subtype, 27/del(7q) typically portends chemoresistance and poor survival. Despite this clear clinical importance, the key tumor suppressor genes (TSGs) encoded on 7q have remained unclear.
We previously identified a haploinsufficient, myeloid TSG on chromosome band 7q22, CUX1.
7 CUX1 is a nonclustered homeobox transcription factor. 8 The full-length p200 protein has 1 homeodomain and 3 cut repeat DNA-binding domains. CUX1 is highly conserved, ubiquitously expressed, and essential for survival in mice and Drosophila. [9] [10] [11] [12] We demonstrated that haploinsufficiency of the ortholog, cut, led to hemocyte overgrowth and tumor formation in Drosophila melanogaster. Similarly, CUX1 haploinsufficiency gave human HSPC an engraftment advantage in mouse xenotransplants. For personal use only. on July 30, 2018 . by guest www.bloodjournal.org From in the context of normal chromosome 7 alleles independently carry a poor prognosis. 14, 17 CUX1 is also recurrently mutated in clonal hematopoiesis of indeterminate potential (CHIP), [18] [19] [20] [21] indicating that CUX1 mutations provide HSPC with a competitive advantage and predisposition for transformation. 22 Further, CUX1 is mutated in a variety of solid tumors; thus, it may regulate tumorigenesis more generally. 7, 17 We reported CUX1 global genomic targets by chromatin immunoprecipitation-sequencing in 3 human cell types, including the K562 myeloid leukemia cell line. 23 CUX1 preferentially bound distal, active enhancers and controlled expression of cell-cycle regulators. 23 CUX1 fit an analog model of dose-sensitive gene regulation, 23 which may provide a nuanced means for CUX1 control of a disparate array of cellular programs (including proliferation, differentiation, and apoptosis) across a broad array of cell types, and even with a single cell type. [24] [25] [26] To identify the in vivo functions for CUX1 in mice, it was essential for us to take a nontraditional genetic approach because of the complexity of the gene. Cux1 is large, ranked in the top 2.1% of mammalian genes by size. Cux1 has 33 exons, more than ;97% of other murine genes. Cux1 shares exons with Casp, a gene encoding a Golgi-associated protein. 8, 27 In addition, Cux1 has 3 alternative start sites and 7 RNA splice isoforms. 27 Traditional knockout mice had unanticipated alternative splicing that removed the inserted STOP cassettes, causing hypomorphic protein expression and incomplete Cux1 knockouts. 12, [28] [29] [30] Previous models also had perinatal lethality and extrahematopoietic effects. 12, [28] [29] [30] To circumvent these issues, we engineered inducible Cux1 short hairpin RNA (shRNA) knock-in mice. 31 We report that CUX1 knockdown led to MDS and MDS/MPN with features of human disease. Our results also demonstrate that reduction of a single 7q gene, Cux1, is sufficient to cause myeloid disorders, and Cux1 is a critical regulator of hematopoietic stem cell (HSC) homoeostasis.
Methods
Complete methods are provided in the supplemental Methods, available on the Blood Web site.
Results

CUX1 is haploinsufficient in human myeloid malignancies
We previously reported that CUX1 is expressed at ;50% levels in de novo AML and therapy-related myeloid neoplasms with 27/del(7q). 7 We extended this finding by first analyzing The Cancer Genome Atlas AML data.
32 CUX1 has 7 RefSeq isoforms; 3 encode the CUX1 DNA-binding transcription factor and the others encode the Golgi-associated CASP protein. 8, 27 The Cancer Genome Atlas AML RNA-sequencing data were provided at the gene level, wherein CUX1 and CASP isoforms were aggregated to a single gene. This analysis showed 60% residual CUX1/CASP in samples with a deletion spanning CUX1 (supplemental Figure 1A ). To look at this finding in more detail, we parsed the CUX1 and CASP encoding isoforms from our published RNA-sequencing data. 7 The CUX1 isoform, NM_181552, is expressed at 66% residual levels in 27/del(7q) patients (supplemental Figure 1B ). We interrogated MDS and JMML microarray datasets. 33, 34 We divided patients into those with or without 27/del(7q) and removed CASP-specific probes. Across datasets, CUX1 probes showed a range of 20.3 to 20.9 log 2 fold-change reduction (supplemental Figure 1C-E) . In other words, for the majority of patients with 27/del(7q), CUX1 levels do not fall below 50% of the levels expressed in patients with diploid chromosome 7 alleles. These results suggest that for patients with 27/del(7q), the remaining CUX1 allele is expressed and CUX1 is haploinsufficient.
Generation of CUX1 knockdown mouse models
We sought to determine the level of Cux1 in murine hematopoietic lineages, and if the expression pattern is conserved between humans and mice. By quantitative reverse transcription polymerase chain reaction (qRT-PCR), Cux1 is high in long-term HSC (LT-HSC) and lower in short-term HSC (ST-HSC) and myeloid progenitors (MPs). Cux1 increases in differentiated granulocytes and monocytes, compared with granulocyte-monocyte progenitors (GMPs) ( Figure 1A ). This pattern is similar to what we observed in human counterparts. 7 To determine the in vivo role for CUX1 in hematopoiesis, we generated CUX1 knockdown mice using an shRNA approach. 31 We engineered 2 knock-in lines, expressing shRNAs of different specificity, to control for potential off-target effects. Cux1 mid targets exon 5, an exon shared by all Cux1 and Casp isoforms ( Figure 1B ). Cux1 low targets the 39 untranslated region of exon 24, shared only by CUX1-encoding transcripts and not CASPencoding isoforms ( Figure 1B) . The transgenes were knocked in to the endogenous Col1a1 locus and under the control of a tetracycline response element (supplemental Figure 2) . A secondgeneration reverse tet-transactivator, m2-rtTA, is expressed under the ubiquitous ROSA26 promoter. In the presence of doxycycline 
/Sca1
2 ) from Cux1 mid and Cux1 low mice showed 31% 6 8% and 25% 6 18% residual Cux1 transcripts, respectively ( Figure 1D ).
Cux1 mid mice develop MDS with anemia and trilineage dysplasia
We first characterized Cux1 mid mice, which approximate CUX1 haploinsufficiency. Because Cux1 is essential for development, 12 we induced the transgene in 6-to 10-week-old mice. Cux1 mid mice had normal appearance and lifespan. Aged Cux1 mid mice developed a normocytic anemia and thrombocytosis ( Figure 1E ; supplemental Figure 3A ). Although the white blood cell count (WBC) was unchanged, the monocyte and granulocyte frequencies were increased ( Figure 1F ). By 18 months of dox, Cux1 mid mice had mild splenomegaly ( Figure 1G ). Monocytes were expanded in the BM, whereas B lymphocytes were reduced (supplemental Figure 3D ). CUX1 knockdown also led to an expansion of LSK and ST-HSC (supplemental Figure 3E ).
Aged Cux1
mid mice had red blood cell polychromasia, with increased reticulocytes, basophilic stippling, and increased Howell-Jolly bodies ( Figure 1H ). Evidence of dysgranulopoiesis included pseudo Pelger-Huet anomalies and hypersegmentation ( Figure 1Hiii , K-M). Cux1 mid BM had normal cellularity with a marginal increase in erythroid precursors (P 5 .10; Figure 1I ; supplemental Figure 3D ,F). Cux1 mid BM had a marked increase in megakaryocytes, many with dysplasia, including micromegakaryocytes, nuclear hypolobation, and condensed hyperchromatic nuclei ( Figure 1I ). The myelomonocytic cells were maturing with no morphologic increase in blasts.
Cux1
mid splenic architecture was partially disrupted because of red pulp expansion ( Figure 1J ). Although Ren mice had occasional subcapsular megakaryocytes, Cux1 mid mice had increased megakaryocytes throughout the spleen and some micromegakaryocytes with condensed, hyperchromatic nuclei ( Figure 1J ). Giant platelets, which can accompany megakaryocyte dysplasia, were present ( Figure 1N ). The splenic touch preparation revealed dyserythropoiesis, including erythroblasts with binucleation or irregular nuclear contours ( Figure 1O ). There was myeloid cell infiltration of the livers of some Cux1 mid mice ( Figure 1P ). In summary, the findings of anemia with trilineage dysplasia are consistent with a diagnosis of MDS, most similar to refractory cytopenia with multilineage dysplasia (RCMD).
36-38
Spontaneous and fatal MDS/MPN in Cux1 low mice
Compared with Cux1 mid , the Cux1 low line had more rapid and aggressive hematopoietic abnormalities, with a median survival of 275 days of dox ( Unlike Cux1 mid , Cux1 low mice fail to gain weight and have fur loss because of the role of CUX1 in hair follicle morphogenesis (supplemental Figure 5A -B). 29, 39 Almost all Cux1 low mice were euthanized because of weakness and anemia after 9 months of dox. At euthanization, Cux1 low mice had hepatosplenomegaly ( Figure 2D -F). Cux1 low mice had splenic and BM hypercellularity ( Figure 2G ), driven largely by an expansion of monocytes and granulocytes ( Figure 2H ; supplemental Figure 5C ). The T-cell count was also increased in the BM and spleen, comprising an expansion of both CD4
1 and CD8 1 T cells (Figures 2I; supplemental Figure 5D ). In comparison, the B-cell count was decreased in the BM ( Figure 2I ), consistent with the decreased B-cell frequency in the blood ( Figure 2C ). Thus, CUX1 knockdown leads to a spontaneous MPN, anemia, and premature mortality.
We next quantified HSPCs. As with Cux1 mid , Cux1 low mice had an expansion of the LSK compartment ( Figure 2J ; supplemental Figure 5F ). Within this population, ST-HSC and multipotent progenitors (MPPs) had increased numbers, whereas LT-HSC did not. Among the MP, common myeloid progenitors (CMPs) and GMPs exhibited increases numbers, whereas megakaryocyteerythroid progenitors (MEPs) were unchanged ( Figure 2J ). The GMP expansion occurred as early as 1 month after CUX1 knockdown (supplemental Figure 4D ). The LSK expansion was not from decreased apoptosis (supplemental Figure 4E ). These results are consistent with a regulatory function for CUX1 in HSPC homeostasis. Overall, this second mouse line confirms the role of CUX1 in diverse hematopoietic lineages and that the level of CUX1 deficiency affects the severity of hematopoietic and nonhematopoietic phenotypes.
To determine if restoration of CUX1 can reverse the disease process, we reexpressed CUX1 in mice with established disease. For personal use only. on July 30, 2018. by guest www.bloodjournal.org From By 7 months of dox, Cux1 low mice have anemia and leukocytosis, becoming moribund by 8 to 9 months; thus, we withdrew dox after 7 months for a cohort of mice. Within 3 weeks, the peripheral blood indices began to normalize ( Figure 2K ). By 7 weeks after dox withdrawal, hemoglobin levels rise to control levels, the WBC decreases to normal levels, and the mice gain weight (Figures 2K-L; supplemental Figure 6 ). All hematopoietic populations assessed, including HSPC, also normalize (supplemental Figure 6) . Thus, the disease process in Cux1 low mice is dependent on continued CUX1-deficiency and is reversible upon CUX1 restoration.
Trilineage dysplasia and myelomonocytic organ infiltration in Cux1 low mice
Hematopathologic assessment of Cux1 low mice demonstrated increased circulating myelomonocytic cells, occasional myeloblasts (1% to 2% of WBC), and granulocytic dysplasia (Figure 3Ai-iv) . Red cells exhibited polychromasia and anisopoikilocytosis, and giant platelets were observed (Figure 3Av ). Erythroblast dysplasia was evident in splenic touch preparations, similar to Cux1 mid ( Figure 3B ). Cux1 low BM demonstrated decreased erythropoiesis (supplemental Figure 5E ) and maturing myelomonocytic cells with no morphologic increase in blasts ( Figure 3C ). Megakaryocytes were increased, many with dysplasia ( Figure 3C ). The splenic architecture was completely effaced in Cux1 low mice ( Figure 3D ). The expanded red pulp comprised maturing erythroid and myeloid cells and a remarkable expansion of megakaryocytes to a greater extent than Cux1 mid . Myelomonocytic cells were observed infiltrating lymph nodes and nonhematopoietic organs, including liver periportal and sinusoidal areas, lung, and kidney ( Figure 3E-H) .
In summary, low levels of CUX1 led to a striking expansion of mature granulocytes and monocytes in hematopoietic and nonhematopoietic tissues, accompanied by anemia and trilineage dysplasia. In human disease, CMML often has hepatosplenomegaly, normocytic anemia, giant platelets, micromegakaryocytes with abnormal lobation, and myeloid infiltrate of lymph nodes. 38 JMML patients also often have hepatosplenomegaly, normocytic anemia, and myelomonocytic infiltrates of the liver, lung, and lymph nodes 38 ; thus, the disease in Cux1 low mice is classified as a MDS/MPN, akin to CMML-1 and JMML. 36, 38 BM transplants develop transient hematopoietic expansion followed by CUX1 dose-dependent BM failure
To determine the hematopoietic-intrinsic role for CUX1, we performed BM transplants (BMTs) of Cux1 mid , Cux1 low , or Ren BM into lethally irradiated, wild-type recipients. We waited 4 weeks for the transplants to engraft before starting dox ( Figure 4A 
mid BMTs had shorter survival (median, 370 days of dox; Figure 4B) low BMTs also had transient increased platelet counts ( Figure 4C ). In contrast, RBC counts were decreased in Cux1 mid and Cux1 low BMTs during the time course ( Figure 4C ). Mice were euthanized because of weakness and/or anemia, at which time Cux1 low BM recipients had pancytopenia with a macrocytic anemia (Figure 4C-D) . Of the 4 Cux1 mid BM recipients that became diseased, 2 were anemic, all were thrombocytopenic, and none had an elevated WBC count ( Figure 4C ).
At 3 months posttransplant, Cux1
low and Cux1 mid BM and spleen cellularity was normal or increased, similar to nontransplanted mice ( Figure 4E ). In contrast, the BM and spleens tended to be hypocellular in Cux1 low and Cux1 mid BMTs at the time of euthanization ( Figure 4E ). Both Cux1 low and Cux1 mid BMT recipients had remarkable dysplasia in megakaryocyte, erythroid, and granulocyte lineages (supplemental Figure 7) . In sum, the cytopenias and trilineage dysplasia in Cux1 mid and Cux1 low BMT recipients are consistent with MDS, akin to RCMD.
At 3 months of dox, Cux1
low BMT recipients had increased LSK, ST-HSC, MP, and MPP ( Figure 4F ). In stark contrast, most stem and myeloid progenitor populations were significantly depleted in Cux1 low BMT at euthanization ( Figure 4G ). Cux1 mid BMT had decreased myeloid progenitors at euthanization. Decreased HSPC numbers may partly explain the BM failure in these mice. Indeed, secondary Cux1 mid and Cux1 low BMT recipients had a significant reduction in LT-HSC, consistent with impaired HSC selfrenewal ( Figure 4H ). Although Cux1 low secondary BMT exhibited pancytopenia, Cux1 mid secondary BMT did not within 350 days of dox (supplemental Figure 8E-F) . The finding that Cux1 mid secondary BMT had decreased LT-HSC suggests that these mice may ultimately develop anemia over longer times. These data indicate that CUX1 knockdown leads to a transient HSPC expansion followed by depletion, via a hematopoietic-intrinsic mechanism.
These findings led us to test the hypothesis that CUX1-knockdown HSPCs outcompete control cells in short-term For personal use only. [18] [19] [20] [21] In these experiments, dox was given on the day of transplant to assess HSPC engraftment. Within 2 months, both Cux1 mid and Cux1 low outcompeted control cells, specifically in the myeloid lineages ( Figure 4I) ; thus, CUX1 knockdown provides a myeloid clonal advantage for HSPCs.
CUX1 knockdown leads to ineffective erythropoiesis
To better understand the cause of the anemia, we explored erythropoiesis in the mouse models. During erythroid maturation, CD71
1 /Ter119 med (RI) pro-erythroblasts gradually lose CD71 expression as they progress through basophilic (RII), polychromatophilic (RIII), and ultimately orthochromatophilic (RIV) stages followed by enucleation. 40 We gated on all erythroid cells and assessed the proportion of erythroblasts within each of these stages. Aged Cux1 mid mice had a mild decrease in the BM RII population and normal splenic RI-RIV frequencies ( Figure 5A-B) . In contrast, Cux1 low splenic erythroblasts had an increased frequency in RII and a decrease in RIV, with relatively normal BM populations ( Figure 5C-D) . The splenic RII expansion and RIV reduction was recapitulated in Cux1 mid and Cux1 low BMTs 3 months after transplant ( Figure 5E-F) . Thus, in nontransplanted Cux1 low , as well as in Cux1 mid or Cux1 low BM recipients, there is a partial block in progression to the RIV orthochromatophilic erythroblast stage.
Interestingly, at the time of disease in BMT recipients, the RII and RIV frequencies normalized ( Figure 5F ). At this time, the total erythroblast cell count was decreased in the BM of transplant recipients ( Figure 5G ). Because HSC exhibited evidence of exhaustion by this time (Figure 4) , decreased erythropoiesis at euthanization may be largely due to upstream HSC defects, masking downstream erythroblast maturation defects.
We next determined if ineffective erythropoiesis was due to erythroblast apoptosis. After 1 month of dox, the frequency of Annexin V 1 cells was similar in Cux1 low and Ren erythroblast populations, suggesting the anemia is not due to decreased erythroblast survival (supplemental Figure 5G) . In summary, these data indicate that CUX1 is novel transcriptional regulator of red cell development regulating at least 2 stages of erythropoiesis: (1) maintenance of HSCs and (2) progression into the orthochromatophilic erythroblast stage.
CUX1 regulates proliferative and phosphatidylinositol 3-kinase (PI3K) pathways and JMML and 27/del(7q) MDS gene signatures
These findings led to us to determine the genes regulated by CUX1 in primary human HSPC, the normal counterparts thought to give rise to myeloid malignancies. 41 We transduced human CD34
1 cells with shRNA targeting CUX1 or a control shRNA, 7 resulting in approximately 50% and 80% residual CUX1 transcripts ( Figure 6A ). RNA-sequencing analysis identified 339 differentially expressed genes (5% false discovery rate), 81% of which decreased, indicating that CUX1 is primarily at transcriptional activator in this cell type ( Figure 6B-C) .
Gene set enrichment analysis 42 determined that genes preferentially expressed in quiescent HSPC 43 were downregulated after CUX1 knockdown ( Figure 6D ). Conversely, genes preferentially expressed in proliferative HSPC 43 were upregulated. This suggests a transcriptional role for CUX1 in regulating HSPC quiescent vs proliferative states. Genes upregulated by activation of the PI3K/AKT/mTOR pathway (ie, the "Hallmark PI3K AKT MTOR Signaling" gene set), were enriched in upregulated genes, which is notable because increased PI3K signaling is associated with HSC exit from quiescence and proliferation. 44 The Gene Ontology pathway, "Negative regulation of myeloid cell differentiation" was downregulated, indicating CUX1 represses myeloid differentiation. This is in accordance with the myeloid expansion we observed after CUX1 knockdown in vivo. 
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To test whether CUX1-regulated genes are associated with human disease, we compared the transcriptional profile of CUX1-knockdown HSPC to gene signatures from MDS patients. 33 Strikingly, genes that are significantly decreased in 27/del(7q) MDS compared with normal karyotype MDS were also decreased after CUX1 knockdown in human HSPCs For FEZ1  MAFB  PID1  C1QA  FABP3  SMPDL3A  C1QC  IGSF6  C1QB  PLA2G7  HMOX1  HNMT  MS4A7  IFIT1  GPNMB  RGL1  NRP1 SLC7A8  SGPP1  ALS2  TRPM6  SPAG17  KIAA1462  HGF  THSD7A  DHRS9  KCNH1  AP1S3  IL18RAP  SELL   HPGD  DUSP27  RFX8  MS4A2  LPGAT1  HRH4  ENPP3  AGR2  PRG3  ARSB  CXCR1  CLC Figure 6D) . Because of the myelomonocytic phenotype of the MPD in Cux1 low mice, we next assessed if CUX1-regulated genes are enriched for a JMML gene signature. Using microarray data from JMML patients and healthy controls, we found that genes upregulated in JMML are enriched for genes upregulated after CUX1 knockdown ( Figure 6D) . Thus, the CUX1 gene signature is associated with JMML and 27/del(7q) MDS disease states, consistent with the JMML and MDS phenotypes of the CUX1 knockdown mice.
CUX1 knockdown induced genes upregulated by PI3K signaling ( Figure 6D ), implying increased PI3K activity. Indeed, Cux1 low BM cells have increased phosphorylation of the PIK3 substrate, AKT ( Figure 6E ). These data align with reports that CUX1/Cut suppresses PI3K activity, 17, 45 by transcriptionally activating expression of the PI3K inhibitor, PIK3IP1. 17 In agreement, we determined CUX1 knockdown leads to decreased Pik3ip1 in Cux1 low LSK and MP ( Figure 6F ). Although Cux1 mid LSKs had a slight decrease in Pik3ip1, we did not reliably detect increased phospho-AKT in Cux1 mid whole BM. Perhaps BM heterogeneity masks putatively increased phospho-AKT in rare HSPC in Cux1 mid mice. Overall, these findings fit a model wherein CUX1 knockdown leads to decreased PI3KIP1, increased PI3K activity, and resulting in increased stem/progenitor cell-cycle entry.
CUX1 regulates HSPC homeostasis
To further understand the role of CUX1 in HSPC differentiation and self-renewal, we performed colony-forming unit (CFU) and serial replating assays. Because CUX1 knockdown alters HSPC populations, we used BM from dox-naïve mice and provided dox only during the assay. Cux1 low BM had a significant increase in CFU on passage 1 ( Figure 7A ; supplemental Figure 9 ). CUX1 knockdown colonies were larger than Ren, particularly Cux1 low at passage 1 and Cux1 mid at passage 2 (supplemental Figure 9) . Indeed, the number of cells enumerated at the end of most passages was greater for Cux1 low and Cux1 mid , consistent with increased progenitor proliferation ( Figure 7B ). Both Cux1 low and Cux1 mid BM had increased CFU in passages 2 and 3 and extinguished by passage 4 ( Figure 7A ). It is unclear why Cux1 mid CFU increased only after the first passage. Because of the decreased potency of Cux1 mid shRNA, perhaps Cux1 mid lagged Cux1 low in achieving sufficient CUX1 knockdown, resulting in a delayed phenotype. Overall, the CFU results are in agreement with the in vivo data demonstrating temporarily increased HSPC number and proliferation but decreased long-term self-renewal (Figure 4 ). In addition, these in vitro assays further confirm the cell-intrinsic role for CUX1 regulation of HSPCs.
To test if CUX1 is acting at an early stem/progenitor stage to regulate lineage specification, we identified colony morphologies.
We consistently observed that Cux1 low led to an excess of CFUgranulocyte/monocyte (CFU-GM) and a paucity of burst-forming units (BFU-Es, erythroid; Figure 7C ). Cux1 mid also had decreased BFU-Es. Although Cux1
mid BM did not demonstrate increased CFU-GM in this assay, we note that the majority of increased CFU in passages 2 and 3 of serial replating of Cux1 mid BM were CFU-GM ( Figure 7A ). These data concur with the in vivo myelomonocytic expansion and anemia of Cux1 low and Cux1 mid mice and indicate that CUX1 levels control cell fate of early stem and/or progenitor cells.
The elevated PI3K activity upon CUX1 knockdown led us to test the hypothesis that CUX1 knockdown promotes HSC exit from quiescence. 44 Cell-cycle analyses showed a significant reduction in the fraction of Cux1 mid and Cux1 low LT-HSC in the quiescent, G 0 , state and a concordant increase in the fraction of cells in S/G 2 ( Figure 7D-E) . ST-HSC, MPP, and GMP also had an increase in frequency of cycling cells in S/G 2 ( Figure 7D-E) . These findings show that CUX1 knockdown promotes LT-HSC exit from quiescence and cell cycling and are in agreement with the expansion of downstream ST-HSC in vivo and the quiescent and proliferative gene signatures in human HSPC.
Discussion
In our studies, all transplant and nontransplant CUX1 knockdown mouse models had anemia and multilineage dysplasia in common, demonstrating a hematopoietic-intrinsic role for CUX1 reduction in MDS ( Table 1 ). The nontransplanted Cux1 low mice additionally exhibit myelomonocytic expansion, comparable to MDS/MPN. In many ways, the Cux1 low phenotypes were stronger than those of Cux1 mid ; for example, BMT survival, AKT phosphorylation, and fur loss, indicating a dosage effect. A prior study of mice homozygous for deletion of the CUX1 homeodomain (Cux1 HD/HD ) reported only 5.4% were viable and few survived beyond 4 week of age, precluding long-term analysis. 12 However, as with Cux1 low mice, Cux1 HD/HD mice had hair loss, cachexia, and myeloid hyperplasia; elevated tumor necrosis factor was thought to explain some of the extrahematopoietic effects. 12 We speculate that the myelomonocytic expansion in Cux1 low mice is also due to hematopoietic-extrinsic inflammatory cytokines stemming from ubiquitous, low CUX1 levels.
Hematopoietic abnormalities have not been reported for Cux1 HD/wt heterozygous mice. 12 However, based on our work, the phenotype would not be apparent until 18 months; it is unclear how long heterozygous mice were aged in the prior study. In a second Cux1 knock-out mouse model, with deletion of only the first cut repeat domain, no hematopoietic abnormalities were found in heterozygous or homozygous mice at 2-3 weeks of age. 28 This may be due to the young age Gene sets used were: "Quiescent" and "Proliferative" 43 ; GO gene set from the MSig Database, 42 27/del(7q) MDS vs normal karyotype MDS, 33 and JMML. 34 Genes listed are those that had nominal P values of ,.05 (CUX1 knockdown vs control) and were within the GSEA "Core enrichment" results. Our studies show that CUX1 is essential for maintaining HSC quiescence, suppressing HSPC proliferation and self-renewal, and regulating lineage specification and differentiation. We propose a model wherein at the top of the hematopoietic hierarchy, CUX1 promotes LT-HSC quiescence through transcriptional activation of Pik3ip1, thereby limiting growth factor-induced signaling pathways. CUX1 knockdown leads to increased PI3K activity, a central (E) The bar graph represents the mean of 3 biological replicates 6 SEM. All data were analyzed with Student t test, *P # .05, **P # .01, ***P # .001.
activator of the HSC cell cycle, 44 promoting LT-HSC exit from quiescence and proliferation. These LT-HSCs give rise to ST-HSC, expanding the ST-HSC pool and downstream progenitors. Eventually, the HSC exhaust and are depleted, leading to BM failure. These findings are consistent with prior reports that increased PI3K signaling leads to transient HSC proliferative expansion followed by exhaustion. [46] [47] [48] In MPP, loss of CUX1 causes increased proliferation and a myeloid differentiation bias, increasing downstream myeloid progenitor numbers, and ultimately myelomonocytic expansion. CUX1 is also necessary for normal erythroid and megakaryocyte development because CUX1 deficiency led to dysplasia and cytopenia in both lineages. Acting at multiple stages of hematopoiesis, CUX1 reduction generally leads to the mobilization of myeloid progenitors with differentiation defects. Increased proliferation and aberrant differentiation are the cardinal features of myeloid malignancies, and CUX1 deficiency drives both.
Our results shed light on how del(7q) 49, 50 and somatic CUX1 inactivating mutations 18, 19 give a clonal advantage in CHIP. CUX1 haploinsufficiency may provide human HSC with a proliferative advantage that enables mutant HSC to outcompete wild-type counterparts, resulting in clonal expansion, as we observed in competitive transplantation assays. That CUX1 knockdown eventually causes HSC exhaustion provides an intriguing biological explanation for the transient 27 or del(7q) that has been observed in some children and adults. 51, 52 A second genetic alteration may be required to increase the long-term survival and/or self-renewal of 27/del(7q) clones, thereby enabling transformation.
We reported that in one-half of 27/del(7q) cases, the "second hit" is a mutation that results in Ras pathway activation. 53 Oncogenic Ras signaling may provide the enhanced selfrenewal capacity necessary for sustained CUX1-deficient HSC clonal expansion. 54 Of note, effectors of Ras include the PI3K/ AKT/mTOR and Raf/MEK/ERK axes. Our finding that CUX1 knockdown enhances PI3K signaling raises the prospect that CUX1 haploinsufficiency cooperates with Ras by potentiating Ras signaling via increased PI3K activity.
There is evidence for other pathogenic genes on 7q, [55] [56] [57] [58] [59] [60] [61] provoking the notion of a contiguous gene syndrome, wherein haploinsufficiency of multiple TSGs contributes to disease. 62 Nonetheless, our data provide strong evidence that CUX1 knockdown alone is sufficient for MDS and MDS/MPN, especially because the disease was also reversible upon CUX1 restoration. It will be critical to identify how combined haploinsufficiency of 7q genes cooperate in neoplasia, however.
Cut, in Drosophila, is exquisitely dose sensitive and changes in cut levels can result in dramatically different cellular programs, including proliferation, differentiation, and apoptosis, even within the same cell type. [24] [25] [26] Transcription factor dosage can be critical in myeloid differentiation and transformation, as evidenced, for example, by Pu.1. 63, 64 In future work, it will be important to determine the threshold of CUX1 necessary for maintaining myeloid TSG activity and if changes in CUX1 levels also dictate hematopoietic cell fate, as described for cut in other models. 25, 26 
